Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?
Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor (PPAR)-γ agonists commonly used as insulin-sensitizing drugs for the treatment of type 2 diabetes. In the last decade, PPAR-γ agonists have received increasing attention for their neuroprotective properties displayed in a varie...
Saved in:
Main Authors: | Anna R. Carta, Augusta Pisanu, Ezio Carboni |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2011-01-01
|
Series: | Parkinson's Disease |
Online Access: | http://dx.doi.org/10.4061/2011/689181 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PPAR Agonists and Cardiovascular Disease in Diabetes
by: Anna C. Calkin, et al.
Published: (2008-01-01) -
Dyskinesia in Parkinson's Disease Therapy
by: Anna Rosa Carta, et al.
Published: (2012-01-01) -
PPARγ and Its Agonists in Chronic Kidney Disease
by: Yuhua Ma, et al.
Published: (2020-01-01) -
Role of PPARα and Its Agonist in Renal Diseases
by: Ching-Feng Cheng, et al.
Published: (2010-01-01) -
The Case for the Use of PPARγ Agonists as an Adjunctive Therapy for Cerebral Malaria
by: Lena Serghides
Published: (2012-01-01)